Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: A children's oncology group report

Autor: Wendy B. London, Alan S. Gamis, Tanya M. Trippett, Shirley Hogan, Sharon Gardner, Lu Chen, R. Paul Guillerman, Pedro A. de Alarcon, Cindy L. Schwartz

Publikováno v: Pediatric Blood & Cancer. 62:60-64

Background We assessed the safety and efficacy of ifosfamide and vinorelbine (IV) as a less toxic and effective reinduction regimen for pediatric patients with relapsed or refractory Hodgkin Lymphoma. Procedure This multi-center Children's Oncology G

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ca3adc4171b04f1fdc3fabc19da17875
https://doi.org/10.1002/pbc.25205

Pathways to Improve Student Pharmacists’ Experience in Research

Autor: Ashley Ellis, Shirley Hogan, Katie S. McClendon, Allison M. Bell, Kim G. Adcock, Daniel M. Riche, Leigh Ann Ross

Objective. To describe the implementation of a student research program and to provide outcomes from the initial 4 years’ experience. Design. Students conducted individual research projects in a 4-year longitudinal program (known as Pathway), with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf4ad865b4c17066d9cd02956ba7f978
https://europepmc.org/articles/PMC4469024/

Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: a children's oncology group report

Autor: Tanya M, Trippett, Cindy L, Schwartz, R Paul, Guillerman, Alan S, Gamis, Sharon, Gardner, Shirley, Hogan, Wendy B, London, Lu, Chen, Pedro, de Alarcon

Publikováno v: Pediatric bloodcancer. 62(1)

We assessed the safety and efficacy of ifosfamide and vinorelbine (IV) as a less toxic and effective reinduction regimen for pediatric patients with relapsed or refractory Hodgkin Lymphoma.This multi-center Children's Oncology Group phase II pilot st

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::46ec88fc8337a6f03116318a1c85efb2
https://pubmed.ncbi.nlm.nih.gov/25308760

Transcriptome Analysis of Minimal Residual Disease in Subtypes of Pediatric B Cell Acute Lymphoblastic Leukemia

Autor: Shirley Hogan, Jitsuda Sitthi-Amorn, Betty Herrington, Jeanette Pullen, Catherine M. Gordon, Tejaswi Koganti, Gail Megason, Chindo Hicks

Publikováno v: Clinical Medicine Insights: Oncology, Vol 2015, Iss 9, Pp 51-60 (2015)
Clinical Medicine Insights. Oncology
Clinical Medicine Insights: Oncology, Vol 9 (2015)

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer and the leading cause of cancer-related death in children and adolescents. Minimal residual disease (MRD) is a strong, independent prognostic factor. The objective of this study w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bf60eb4f53098f1c20c555bba1de9f0
https://doi.org/10.4137/cmo.s17049

AHOD0031: A Phase III Study of Dose-Intensive Therapy for Intermediate Risk Hodgkin Lymphoma: A Report From the Children's Oncology Group

Autor: Shirley Hogan, Lu Chen, Nathan L. Kobrinsky, Robert E. Hutchison, Pedro A. de Alarcon, Suzanne L. Wolden, Cindy L. Schwartz, Debra L. Friedman, Meghan A. Higman, Thomas J. Fitzgerald, Tanya M. Trippett, Kathleen M. McCarten, Peter F. Ehrlich, Lorna Roll, Allen R. Chen, Louis S. Constine

Publikováno v: Blood. 116:766-766

Abstract 766 The challenge in treating children with Hodgkin lymphoma (HL) is to continue progress in its curability while diminishing the risk for toxic events that compromise quality of life and survival. This therapeutic Phase III trial for patien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2f4f75147f5ad6c2c1795058fa2a2932
https://doi.org/10.1182/blood.v116.21.766.766